Press Releases

December 16, 2024 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Dec. 16, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today

PDF Version
November 26, 2024 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO --(BUSINESS WIRE)--Nov. 26, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today

PDF Version
November 18, 2024 at 8:00 PM EST

Summary Toggle Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

SAN DIEGO --(BUSINESS WIRE)--Nov. 18, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today

PDF Version
November 14, 2024 at 1:00 AM EST

Summary Toggle Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

TOKYO --(BUSINESS WIRE)--Nov. 14, 2024-- Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan , President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as " Meiji Seika Pharma ") today announced its investment in ARCALIS, Inc.

PDF Version
November 11, 2024 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

SAN DIEGO --(BUSINESS WIRE)--Nov. 11, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today

PDF Version
November 7, 2024 at 4:01 PM EST

Summary Toggle Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Cystic Fibrosis and OTC Deficiency Phase 2 studies on track for POC data in first half of 2025 $25 Million commercial milestone achieved with first sale of KOSTAIVE® in Japan KOSTAIVE® European CHMP opinion expected December Positive results from multiple Phase 3 studies support KOSTAIVE® U.S.

PDF Version
October 31, 2024 at 4:01 PM EDT

Summary Toggle Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

SAN DIEGO --(BUSINESS WIRE)--Oct. 31, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA vaccines and medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and

PDF Version
September 30, 2024 at 8:00 AM EDT

Summary Toggle Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Head-to-head data, presented at OPTIONS XII for the Control of Influenza Conference, demonstrates advantage of sa-mRNA over conventional mRNA in duration of immune response; Results highlight CSL and Arcturus Therapeutics’ commitment to advancing COVID-19 vaccine innovation to protect public

PDF Version
September 13, 2024 at 8:00 AM EDT

Summary Toggle Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Approval underscores CSL and Arcturus Therapeutics’ commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE ® , the world’s first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of

PDF Version
September 3, 2024 at 8:30 AM EDT

Summary Toggle Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

SAN DIEGO --(BUSINESS WIRE)--Sep. 3, 2024-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease vaccines and addressing unmet medical needs within liver and respiratory rare

PDF Version